Originally published In Press as doi:10.1074/jbc.M208882200 on September 10, 2002
J. Biol. Chem., Vol. 277, Issue 47, 45537-45546, November 22, 2002
Dual-substrate Specificity Short Chain Retinol Dehydrogenases
from the Vertebrate Retina*,
Françoise
Haeseleer
§,
Geeng-Fu
Jang
§,
Yoshikazu
Imanishi
§,
Carola A. G. G.
Driessen¶,
Masazumi
Matsumura
,
Peter S.
Nelson
, and
Krzysztof
Palczewski
**
§§
From the Departments of
Ophthalmology,
** Pharmacology, and 
Chemistry,
University of Washington, Seattle, Washington 98195, ¶ Department of Biochemistry, University of Nijmegen, 6500 HB
Nijmegen, The Netherlands, and
The Division of Human Biology,
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109
Received for publication, August 30, 2002, and in revised form, September 9, 2002
 |
ABSTRACT |
Retinoids are chromophores involved in vision,
transcriptional regulation, and cellular differentiation. Members of
the short chain alcohol dehydrogenase/reductase superfamily catalyze
the transformation of retinol to retinal. Here, we describe the
identification and properties of three enzymes from a novel subfamily
of four retinol dehydrogenases (RDH11-14) that display dual-substrate specificity, uniquely metabolizing all-trans- and
cis-retinols with C15 pro-R
specificity. RDH11-14 could be involved in the first step of
all-trans- and 9-cis-retinoic acid production
in many tissues. RDH11-14 fill the gap in our understanding of
11-cis-retinal and all-trans-retinal
transformations in photoreceptor (RDH12) and retinal pigment epithelial
cells (RDH11). The dual-substrate specificity of RDH11 explains the
minor phenotype associated with mutations in 11-cis-retinol
dehydrogenase (RDH5) causing fundus albipunctatus in humans
and engineered mice lacking RDH5. Furthermore, photoreceptor RDH12 could be involved in the production of
11-cis-retinal from 11-cis-retinol during
regeneration of the cone visual pigments. These newly identified
enzymes add new elements to important retinoid metabolic pathways that
have not been explained by previous genetic and biochemical studies.
 |
INTRODUCTION |
Retinoids are indispensable light-sensitive elements of vision and
also serve as essential modulators of cellular differentiation and
proliferation in diverse cell types, including those comprising the
epithelium and immune system. Retinoids modulate the growth of both
normal and malignant cells through their binding to retinoid receptors.
All-trans-retinoic acid signals through specific
interactions with the nuclear retinoic acid receptors, whereas its
isomer, 9-cis-retinoic acid, is a high affinity ligand of
retinoic acid receptors and retinoid X receptors. In the retina,
light-dependent photoisomerization of
11-cis-retinylidene to the all-trans-retinylidene moiety of rod and cone photoreceptors is a key reaction that triggers visual sensation (1). Restoration of the visual chromophore occurs
through a complex set of reactions, termed the retinoid cycle, in
photoreceptor cells and adjacent retinal pigment epithelial cells
(RPE)1 (2). Dietary
deficiencies in retinoids and retinoid precursors cause visual
impairment, developmental abnormalities, and immune deficiency (3,
4).
Transformations of retinoids occur mostly through enzymatic or
photochemical reactions, although they readily isomerize
non-enzymatically to thermodynamic equilibrium when unprotected by the
retinoid-binding proteins (5). The key enzymes involved in retinoid
metabolisms are alcohol and aldehyde dehydrogenases that convert
retinols to aldehydes and aldehydes to carboxylic acids, respectively. The first oxidation reaction is catalyzed by a large number of enzymes
from the SDR superfamily (6, 7) and by classic medium chain alcohol
dehydrogenases (8). SDRs are weakly conserved in their primary
sequences, with the exception of key residues involved in catalysis,
nucleotide recognition, and members of closely related subfamilies.
SDRs also display NADP or NAD cofactor preference and, if they are
retinol dehydrogenases (RDHs), favor all-trans- or
cis-retinol substrates. Some RDH enzymes also catalyze the
oxidation of steroids in addition to retinols (9). Localized expression
of these enzymes in the photoreceptor and RPE cells, where heavy
traffic of diffusible retinoids occurs, strongly suggest that retinols
and retinals are their in vivo substrates. The role of
specific SDRs in vision has been determined from the biochemical characterization of enzymes isolated from specific compartments of the
retina, analyses of retinoid flow in genetically engineered mice, and
from associations of human visual dysfunctions with specific disabling
mutations in one of the SDR genes, RDH5 (for review,
see Ref. 2).
The present study was undertaken to resolve the discrepancy between
biochemical and genetic analyses of the RDH activity responsible for
11-cis-retinal and 9-cis-retinal production. An
enzyme encoded by the RDH5 gene (10, 11),
11-cis-RDH, was proposed to be responsible for both
11-cis-retinal and 9-cis-retinal production due
to its relaxed substrate specificity (12-15). However, the disruption
of this gene in a mouse model led to uninterrupted production of
11-cis-retinal (16, 17) and a lack of any embryonic abnormalities. Furthermore, patients with fundus albipunctatus who also
have a disabling mutation in the RDH5 gene still show efficient production of the chromophore, albeit with slower kinetics (18, 19). Here, we characterized members of a novel subfamily of SDRs
cloned from the retina that display novel properties of dual
cis- and all-trans-retinol substrate
specificities. The recognition of both types of isomers studied by
stereospecific substrates unravels a novel mode of substrate
recognition. The RDH11 transcript has been previously identified as one
that exhibits increased expression on exposure to androgens in the
LNCaP prostate cancer cell line (20) and is proposed to be involved in
the metabolism of retinoids (21).
 |
MATERIALS AND METHODS |
Cloning of Human RDH11-14--
Full-length RDHs were amplified
by PCR from human (RDH11-13) or mouse (RDH14) retina cDNA
libraries using primers FH497 (5'-GAGATGGTTGAGCTCATGTTC-3') and FH498
(5'-GTTAGTCTATTGGGAGGCC3-') for RDH11, FH500
(5'-acgatgctggtcaccttgggactg-3') and FH501
(5'-ACGATGCTGGTCACCTTGGGACTG-3') for RDH12, FH502
(5'-ATGAGCCGCTACCTGCTGCCG-3') and FH503 (5'-TTATCTGGGGAGGGGCTGCTC-3')
for RDH13, and FH490 (5'-GTTATGGCAGTGGCTAGTGTGG-3') and FH491
(5'-CTATTTTAGAATGCCAACCATCACTT-3') for RDH14. The reactions were
cycled through 35 cycles of 94 °C for 30 s and 68 °C for 2.5 min followed by 7 min at 68 °C. The PCR products were cloned in the
pCRII-TOPO vector (Invitrogen) and sequenced by dideoxyterminator sequencing (ABI-Prism, PerkinElmer Life Sciences).
Expression of RDH12-14 in Escherichia coli--
The coding
sequences for RDH12 and RDH14 were cloned as a fragment into
BamHI-XhoI or EcoRI-XbaI
sites in pMAL-c2X (New England Biolabs). This joins RDH12 and RDH14 in
fusion with the maltose-binding protein. RDH12 and RDH14 were expressed
in TOP10 bacteria after induction with 0.5 mM
isopropyl-1-thio-
-D-galactopyranoside and purified on an
amylose column according to the manufacturer's protocol. The coding
sequence for RDH13 was cloned into EcoRI-digested pET30A.
This fusion construct joins RDH13 to a His6 tag.
RDH13 was expressed in BL21 bacteria after induction with 0.2 mM isopropyl-1-thio-
-D-galactopyranoside and
purified on a Ni2+-nitrilotriacetic acid column in
denaturing conditions according to the manufacturer's protocol (Qiagen).
Expression of RDH11, RDH12, and RDH14 in Insect and ARPE19
Cells--
The coding sequence of human RDH11, human RDH12, human
RDH13, or mouse RDH14 was transferred as a
NotI-KpnI fragment in
NotI-KpnI-digested pFASTBac. Recombinant RDH
baculoviruses were then obtained by transposition in DH10BAC bacteria
and amplified after transfection in SF9 cells. The expression of
recombinant proteins was tested 3 days after transfection, and the
cells were collected for enzymatic assays. ARPE19 cells were
transfected with baculoviruses, and expression was driven by the
cytomegalovirus promoter as described previously (22).
Immunocytochemistry and in Situ Hybridization--
The in
situ hybridization techniques and preparation of the mouse,
bovine, human and monkey retinal sections were carried out as described
previously (23). cDNA fragments of mouse and human RDH12 were
cloned into PCRII-TOPO vectors and linearized with appropriate
endonucleases. Antisense and sense RNA probes (0.9-1 kb) were
synthesized by run-off transcription from the SP6 or T7 promoter with
digoxigenin-UTP, as recommended in the manufacturer's protocol (Roche
Molecular Biochemicals).
For immunohistochemistry, retinal sections were blocked for nonspecific
labeling by incubating in 1.5% normal goat serum in PBST buffer (136 mM NaCl, 11.4 mM sodium phosphate, 0.1% Triton X-100, pH 7.4) for 15 min at room temperature. Sections were incubated with purified anti-RDH11 monoclonal antibody or anti-RDH13 serum overnight at 4 °C. Controls were prepared by absorbing the
antibodies with an excess amount of RDH11 peptide (0.5 µg/ml) or
purified RDH13 (2 µg/ml). Sections were rinsed in PBST and incubated
with indocarbocyanine (Cy3)-conjugated goat anti-mouse IgG. Sections were then rinsed in PBST and mounted in 50 µl of 2%
1,4-diazabicyclo-2,2,2-octane in 90% glycerol to slow photobleaching.
Sections were analyzed under a confocal microscope (Zeiss LSM510).
Bright field images were captured with Nomarski optics (NIKON).
Preparation of Anti-RDH11, -RDH13, -RDH14, and -RDH5--
The
antibody against RDH11 was generated against
CHVAWVSVQARNETIAR-CONH2 peptide (21). Bacterially expressed
and purified RDH13 and RDH14 were used to immunize BALB/c mice to
obtain anti-RDH13/14 antisera. Mouse anti-RDH5 monoclonal antibodies
were raised against RDH5-His6 purified from
RDH5-His6-infected Sf9 cells (24).
Retinoids--
All reactions involving retinoids were carried
out under dim-red light conditions. Retinoids were stored in
N,N-dimethylformamide under argon at
80 °C.
Retinoids were purified by normal phase HPLC (Beckman Instruments,
Ultrasphere-Si, 4.6 mm × 250 mm) with 10% ethyl acetate, 90%
hexane at a flow rate of 1.4 ml/min using an HP1100 with an on-line
diode-array detector and HP Chemstation A.06.03 software.
Preparation of Proteins--
Fresh bovine eyes were obtained
from a local slaughterhouse (Schenk Packing Co., Inc., Stanwood, WA).
ROS membranes were isolated from bovine retina using the sucrose
gradient centrifugation method (25). RPE microsomes were prepared as
described previously (26). Expression of RDH5 with a His6
tag at the carboxyl terminus in Sf9 cells was reported
previously (24). Horse liver alcohol dehydrogenase (Sigma/Aldrich) was
purified on a Mono Q HR5/5 (Amersham Biosciences) column equilibrated
with 10 mM BTP, pH 7.3, using a linear gradient from 0 to
500 mM NaCl over 60 min at a flow rate of 0.7 ml/min. The
horse liver alcohol dehydrogenase fraction (eluted at 1-3 min, 0.6 mg/ml) containing the highest dehydrogenase activity when assayed with
pro-R [4-3H]NADH, and
all-trans-retinal or 11-cis-retinal was used in
further studies (24). L-Glutamic dehydrogenase
(Sigma/Aldrich) was dialyzed against 10 mM BTP, pH 7.3, 0.1 M NaCl before use.
Preparation of Pro-R [4-3H]NADH, Pro-S
[4-3H]NADH, Pro-R [4-3H]NADPH, and Pro-S
[4-3H]NADPH--
The preparation of pro-R
[4-3H]NADH was accomplished by utilizing the
pro-R-specific enzyme yeast alcohol dehydrogenase (Sigma) to
reduce NAD with 1-3H-labeled EtOH (American Radiolabeled
Chemicals, Inc.) as previously described (16). Syntheses of
pro-S [4-3H]NADH and pro-S
[4-3H]NADPH were carried out with L-glutamic
dehydrogenase (Sigma), NAD(P) (Sigma), and
L-[2,3-3H]glutamic acid (PerkinElmer Life
Sciences) as previously described (19). Synthesis of pro-R
[4-3H]NADPH was prepared with L-glutamic
dehydrogenase, [4-3H]NADP, and L-glutamic
acid, as described previously (24). The product was purified on a Mono
Q HR 5/5 column equilibrated with 10 mM BTP, pH 7.3, using
a linear gradient from 0 to 500 mM NaCl over 60 min at a
flow rate of 0.7-1 ml/min. Concentrations of NADH and NADPH (pH 7.4)
were determined using
= 6,220 at 340 nm, and concentrations of
NAD and NADP (pH 7.4) were determined using
= 18,000 at 260 nm
(27).
Preparation of Pro-R,S-9-cis-[15-3H]retinol,
Pro-R,S-11-cis-[15-3H]retinol, and
Pro-R,S-all-trans-[15-3H]Retinol and Their Corresponding
15-3H-Labeled
Retinals--
Pro-R,S-9-cis-[15-3H]retinol,
pro-R,S-11-cis-[15-3H]retinol,
and
pro-R,S-all-trans-[15-3H]retinol
were prepared by the reduction of their respective retinals with
[3H]NaBH4 (PerkinElmer) as described before
(24). [15-3H]Retinal was synthesized by MnO2
oxidation of the corresponding pro-R,S-[15-3H]retinol as previously described
(24).
Syntheses of Stereospecific 15-3H-Labeled
Retinols--
Table I summarizes the
syntheses of various stereospecific 15-3H-labeled retinols
by different dehydrogenases. pro-R and pro-S designations were used for 15-3H-labeled retinols produced
by the enzyme for which the stereospecificity is known (24).
Assay for RDH Activity--
Activities of RDHs (recombinant
Sf9 cells suspended in 20 mM BTP, pH 7.4, 0.25 mM n-dodecyl-
-D-maltoside, 1 mM DTT, 1 µM leupeptin, 10 µM
NAD and NADP (0.9-1.81 mg/ml)) were assayed by monitoring the
production of either [15-3H]retinol (reduction of
retinal) or [4-3H]NADPH (oxidation of retinol) (24, 28).
RDH activities were measured using the phase partition assay (29) or
HPLC assays as described (24).
Preparation of RDH5 Affinity Column--
Monoclonal anti-RDH5
antibody was purified on a protein-A column, and then the purified
antibody was coupled to CNBr-activated Sepharose 4B (Amersham
Biosciences) following the manufacturer's procedures.
Purification of RDH5 and RDH5-His6 from Bovine RPE
Microsomes and RDH5-His6-transfected Sf9 Cells,
Respectively--
RPE microsomes (1.3 ml, 5 mg/ml) were solubilized
with 5 mM n-dodecyl-
-D-maltoside
in the presence of 20 mM BTP, pH 7.4, 1 mM DTT,
and 1 µM leupeptin (buffer A) with 20 µM
NAD and NADP for 60 min on ice. The solubilized mixtures
were centrifuged at 71,700 × g for 40 min, and the
supernatant was loaded onto the monoclonal anti-RDH5 antibodies
Sepharose 4B (~0.6 ml of gel) equilibrated with buffer A. The column
was then washed with 12 ml of the same buffer, RDH5 was eluted by 45 mM sodium citrate, pH 3.0, 5 mM
n-dodecyl-
-D-maltoside, and 1 mM
DTT, and the fraction was immediately neutralized with 1.35 M Tris-HCl, pH 8.8, to ~pH 6-7. The purification of
RDH5-His6 from the transfected Sf9 cells (~1.5 ml
of cell pellets) was carried out similarly except using solubilization
buffer at a final volume of 6 ml and 1 ml of gel.
RDH Assays with Sepharose-Antibody-bound
RDHs--
Sepharose-antibody-bound RDH activities and substrate
specificities were carried out by monitoring the production of
[15-3H]retinol (reduction of retinal) (24). The reaction
mixture (150 µl) contained MES (final concentration, 70-74
mM, pH 5.5), DTT (1 mM), pro-S
[4-3H]NADH (26 µM), or pro-S
[4-3H]NADPH (26 µM), 20-25 µl of
Sepharose-antibody-bound RDH gel suspension (suspended in 2× volumes
of buffer A) in the presence or absence of NAD(P)H (520 µM), and 2 µl of retinal (120-140 µM) substrate stock was added last to initiate the reaction. The reaction was incubated at 37 °C for 50 min then terminated with 400 µl of
methanol and 100 µl of 1 M NaCl and extracted with 500 µl of hexane. Radioactivity was measured in the organic phase by
scintillation counting.
 |
RESULTS |
Initial screening of prostate short chain dehydrogenase/reductase
I (PSDR1) expression, an enzyme cloned by Nelson and co-workers (20)
from prostate epithelium, reveals that this enzyme is also expressed in
the eye (data not shown). Therefore, the name PSDR1 was changed into
RDH11 to reflect its broader expression.
RDH11-14 Sequence Analyses and Gene Structures--
Nucleic acid
and protein sequence databases were searched with the RDH11 cDNA
sequence (identical to the sequence of the PSDR1 gene
product (20)) using Blast. This search identified full-length cDNA
clones that show homology to RDH11 and encode RDH12 (first deposited by
T. Isogai and under accession number AK054835), RDH13 (expressed
sequence tag (EST) deposited by R. Strausberg and under accession
number BE736147), and RDH14 (also named PAN2 and deposited by Z. Krozowski under accession number AF237952). The analysis of these
cDNAs shows open reading frames of 316, 331, and 336 amino acids
for RDH12, RDH13, and RDH14, respectively, encoding proteins of ~35,
~36, and ~37 kDa. RDH11 shares 79% similarity with RDH12 and
~60% similarity with RDH13 and RDH14. RDH12, RDH13, and RDH14 share
~60% similarity among themselves (Fig.
1, A and B).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Primary sequences and the gene structures of
RDHs expressed in the retina. A, alignment of the
deduced amino acid sequences of human RDH11 (AF167438), human RDH12
(sequence identical to unnamed XM_085058), human RDH13 (sequence
identical to unknown AAH09881), human PAN2 (RDH14) (NM_020905), human
RDH5 (HSU43559), human prRDH (NM_015725), and human retSDR1 (AF061741).
The identical residues in all sequences are shown in white
letters on a black background. The identical residues
in RDH11-14 sequences are shown in dark gray. The conserved
residues in RDH11-14 sequences are shown in light gray. The
amino acids used to develop anti-RDH11 monoclonal antibodies are
indicated by white letters on the black
background. B, phylogenetic tree. The tree was built
with a bootstrap analysis of neighbor-joining distance using PAUPSearch
in GCG (Genetics Computer Group). The numbers represent the
percentage of identities with RDH12. The percentage of similarities is
indicated in parentheses. C, gene structure of RDH11-14.
The coding regions are shown as black boxes, and the
noncoding regions are shown as white boxes. The thick
lines and the numbers represent the introns and their
sizes, respectively.
|
|
These proteins contain two motifs highly conserved among SDRs, the
cofactor-binding site (GXXXGXG) and catalytic
residues (YXXXK). SDRs contain a motif at the amino terminus
consisting of
-strand A,
-helix B,
-strand B, and
-helix C
(part of the
A-
B-
B-
C-
C-
D-
D that forms the Rossman
fold), which interacts with the adenosine monophosphate moiety of the
cofactor. The residues present at the junctions
A-
B and
B-
C
are thought to be important in selectivity for NAD(H) versus
NADP(H). For favorable interaction with NADP(H), positively charged
residues are present at the
A-
B junction (glycine-rich motif)
and/or at the beginning of
-helix C (7). For all RDH11-14, no
charged amino acids are present in the Gly-rich motif (GANTGIG for
RDH11-13 or GANSGLG for RDH14), and there are positively charged
residues present at the
B-
C junction (RDVEK,
RDVLK, RDMEK, RDRARA for RDH11, -12, -13, and -14, respectively), suggesting a preference for NADP/NADPH (Fig. 1A).
The tissue distribution of RDH11-14 was deduced from the array of ESTs
displayed in databases corresponding to these RDHs. RDH11 was reported
to be expressed abundantly in prostate tissue but also in eye, kidney,
pancreas, liver, testis, heart, and brain (20). In addition, ESTs
corresponding to RDH11 were also found in libraries from eye, skin, and
muscle. ESTs matching RDH12 were identified in multiple tissues, most
of them from eye, but also some from kidney, brain, skeletal muscle,
and stomach. RDH13 ESTs were obtained mostly from eye, pancreas,
placenta, and lung. Many ESTs from brain, kidney, pancreas, and
placenta correspond to RDH14.
Genomic clones were identified by GenBankTM data base
searches with the coding sequences of the RDHs. Clone
Hs14_10185 contains both entire human RDH11 and
RDH12 genes. The RDH11 gene is located ~30 kb
from the RDH12 gene in the 3'-RDH11-5'
5'-RDH12-3' orientation. This genomic clone originates from
chromosome 14 at q23.3. These genes are located at the locus for a
recessive blinding disease, Leber's congenital amaurosis 3 (LCA3)
(www.sph.uth.tmc.edu/Retnet). Clone AC011476.7, obtained from
chromosome 19 at q13.42, contains the complete RDH13 gene.
Clone Hs2_16082 contains the RDH14 gene and originates from
chromosome 2 at p24.1. Comparison of the RDH cDNAs with
these genomic clones solved the gene structures. The gene structures of
RDH11, RDH12, and RDH13 are almost
identical and are interrupted by six introns. The intron/exon junctions of RDH11 and RDH12 are at the same positions,
whereas intron 6 of RDH13 is positioned 35 amino acids
upstream compared with intron 6 of RDH11 and
RDH12. RDH14 has only one intron, which is
located at the same position as intron 3 of RDH11,
RDH12, and RDH13, and is a relatively small gene
(~6 kb compared with 13-18 kb for the RDH11-13) (Fig.
1C). This gene structure is different from other SDR
superfamily RDHs expressed in the eye (30-32).
Localization of RDH11-14 in the Eye--
A monoclonal antibody
specific for RDH11 did not cross-react with RDH5, a prominent enzyme
present in the RPE as shown by immunoblotting (Fig.
2A). The lack of
cross-reactivity is apparent because RDH5 and RDH11 have different
molecular masses. Strong immunoreactivity was detected in bovine and
monkey RPE (Fig. 2, C and F) and was blocked by
RDH11 peptides (Fig. 2, D and G). A lower level
of RDH11 expression was also detected in the Müller cells, as
demonstrated by a double immunolabeling study with the Müller
cell marker glial fibrillary acidic protein (Fig. 2H).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 2.
Immunolocalization of RDH11 in bovine and
monkey retina. A, specificity of anti-RDH5 (lane
1) and anti-RDH11 (lanes 2-5) antibodies. Lanes
1 and 2, bovine RPE; lane 3, bovine ROS;
lane 4, Sf9 cell lysate expressing recombinant RDH11;
lane 5, Sf9 cell lysate; lane 6, purified
RDH5-His6. B-D, immunofluorescence localization
of RDH11 in monkey retina. B, control bright field image of
monkey retina. C, RDH11 immunolabeling is predominant in the
RPE cell layer of monkey retina. D, addition of purified
peptide (0.5 µg/ml) abolishes RDH11 immunoreactivity.
E-G, immunofluorescence localization of RDH11 in bovine
retina. E, control bright field image of bovine retina.
F, RDH11 immunolabeling is predominant in the RPE cell layer
of bovine retina. G, addition of purified peptide (0.5 µg/ml) abolishes RDH11 immunoreactivity. Bar, 50 µm.
H, co-localization of RDH11 and glial fibrillary acidic
protein in the inner retina. The bovine retina section was
double-labeled with antibodies to glial fibrillary acidic protein and
RDH11. Arrows show the colocalization of glial fibrillary
acidic protein (green) and RDH11 (red) in
Müller cells. Bar, 50 µm. OS,
photoreceptor outer segments; IS, photoreceptor inner
segments; ONL, outer nuclear layer; OPL, outer
plexiform layer; INL, inner nuclear layer; IPL,
inner plexiform layer; GCL, ganglion cell layer;
NFL, nerve-fiber layer.
|
|
A digoxigenin-conjugated RDH12 antisense RNA probe hybridized to the
base of monkey photoreceptor inner segments (Fig.
3, A and B,
left). To visualize the chromogenic signal in RPE cells, an
albino mouse retina was examined in this study (Fig. 3B). In albino mouse (BALB/c) retina (Fig. 3B, left),
signals were not observed in the RPE cell layer. As a negative control,
the sense RDH12 RNA probe did not produce significant hybridization
signals in monkey or mouse retina (Fig. 3, A and
B, right). No specific anti-RDH12 antibodies have
been generated so far.

View larger version (126K):
[in this window]
[in a new window]
|
Fig. 3.
In situ hybridization of monkey
and mouse RDH12. A, in situ hybridization of
RDH12 transcripts in monkey retina using antisense (left)
and sense (right) RNA. The strongest signal is detected in
photoreceptor (cones and rods) inner segments and cell bodies.
B, in situ hybridization of RDH12 transcripts in
mouse retina using antisense (left) and sense
(right) RNA. The strongest signal is detected in
photoreceptor inner segments. Bar, 50 µm. RPE,
retinal pigment epithelium; OS, photoreceptor outer
segments; IS, photoreceptor inner segments; OLM,
outer limiting membrane; ONL, outer nuclear layer;
OPL, outer plexiform layer; INL, inner nuclear
layer; IPL, inner plexiform layer; GCL, ganglion
cell layer; NFL, nerve-fiber layer.
|
|
Antibodies recognizing RDH13 (Fig.
4A) labeled inner segments of
the photoreceptor cells of human and monkey retina (Fig. 4,
C and F). Weak signals were observed in a small
population of inner nuclear neurons and the inner plexiform layer.
Higher magnification images localized RDH13 expression to inner
segments of rod and cone photoreceptors (Fig. 4H,
inset). This immunoreactivity is specific as it was blocked
by purified RDH13 protein. RDH14 yielded hybridization signals in the
photoreceptor nuclear layer, and this enzyme appears to be expressed at
low levels in the eye, although RDH14 immunolabeling was clearly
observed in the bovine cone and ROS with a weaker signal in
Müller cells (Supplemental Fig. 1).

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 4.
Immunolocalization of RDH13 in human and
monkey retina. A, specificity of anti-RDH13 antibodies.
Lane 1, SF9 cell lysate expressing recombinant RDH11;
lane 2, SF9 cell lysate expressing recombinant RDH12;
lane 3, SF9 cell lysate expressing recombinant RDH13;
lane 4, SF9 cell lysate expressing recombinant RDH14;
lane 5, monkey retinal homogenate; lane 6, human
retinal homogenate. B-D, immunofluorescence localization of
RDH13 in human retina. B, bright field image of human
retina. C, RDH13 immunolabeling is predominant in the
photoreceptor inner segments of human retina. Weak signals were
observed in the inner plexiform layer and inner nuclear neurons
proximal to the outer plexiform layer. D, addition of
purified RDH13 (2 µg/ml) abolishes RDH13 immunoreactivity.
E-G, immunofluorescence localization of RDH13 in monkey
retina. E, bright field image of monkey retina.
F, RDH13 immunolabeling is predominant in the photoreceptor
inner segments of monkey retina. Weak signals were observed in inner
plexiform layer and inner nuclear neurons proximal to the outer
plexiform layer. Bar, 50 µm. G, addition of
purified RDH13 (2 µg/ml) abolishes RDH13 immunoreactivity.
H, localization of RDH13 (red) in monkey retina.
The cone sheath was simultaneously visualized by fluorescein-conjugated
peanut agglutinin (green). Inset, higher
magnification image. Arrows show the localization of RDH13
(red) in cone inner segments surrounded by the cone sheath
(green). Asterisks indicate the localization of
RDH13 in rod inner segments. Bar, 50 µm. RPE,
retinal pigment epithelium; OS, photoreceptor outer
segments; IS, photoreceptor inner segments; ONL,
outer nuclear layer; OPL, outer plexiform layer;
INL, inner nuclear layer; IPL, inner plexiform
layer; GCL, ganglion cell layer; NFL, nerve-fiber
layer.
|
|
RDH Activity of RDH11, RDH12, and RDH14--
RDH11 catalyzed the
reduction of all-trans-retinal and its 9-cis-,
11-cis-, and 13-cis-retinal isomers. The activity
was observed in the presence of NADPH and with Sf9 insect cell
membranes only when Sf9 cells were transfected with the cDNA
encoding RDH11 (Fig. 5). The products
were clearly identified by the characteristic spectrum for each retinol
isomer and a retention time that was similar to authentic standards
(Fig. 5). This analysis avoids problems associated with the
isomerization among retinols during incubation or sample handling. The
activity toward 13-cis- was the lowest of the retinoid
substrates tested and was only detected using high sensitivity HPLC
analysis. The summary of the product conversion is illustrated in Fig.
6A. RDH12 and RDH14 have very similar properties to those of RDH11 (Fig. 6, B and
C). However, RDH13, expressed in insect cells (Fig. 4),
displayed no RDH activity. The double specificity exhibited by RDH11,
RDH12, and RDH14 toward cis- and
all-trans-retinoids makes these enzymes unique among short
chain RDHs.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
RDH activity with various isomers of retinals
and NADH and NADPH dinucleotides. In each panel, the
first (from the top) and third chromatograms were
from bacmid in Sf9 cells with NADH (solid
lines) and NADPH (dashed lines) as dinucleotide
substrates, respectively. The second and fourth chromatograms were from
recombinant RDH11 expressed in Sf9 cells using NADH
(dotted lines) and NADPH (dashed-dotted lines) as
dinucleotide substrates, respectively. Retinols (indicated by
arrows identifying specific elution times and spectra
(insets)) were only produced when RDH11 expressed in
Sf9 cells and NADPH were used. The assays (reduction of
retinals) were carried out using non-radiolabeled retinals (90 µM) and dinucleotides (50 µM), as described
under "Materials and Methods." The retinoids were separated using a
normal phase HPLC column (Beckman, Ultrasphere-Si, 2.1 mm × 250 mm) developed with 10% ethyl acetate, 90% hexane at a flow rate of
0.5 ml/min. Note that the spontaneous isomerization of retinal
generated a mixture of aldehydes, for example
all-trans-retinal (1) is contaminated by
13-cis-retinal (4), and the production of
13-cis-retinol is at the level of background (fourth
panel). mAU, milliabsorbance units.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
Stereoisomeric specificities of
RDH11-14. A-C, different geometric isomers of
retinals (1, all-trans-retinal; 2,
9-cis-retinal; 3, 11-cis-retinal;
4, 13-cis-retinal, 90 µM each) were
tested with various RDHs in the presence of stereospecifically
radiolabeled pro-S [4-3H]NADPH (18 µM). The assay (reduction of retinals) and HPLC
conditions were the same as in Fig. 5. The corresponding retinol
fraction was collected and subjected to scintillation counting.
D, stereospecifically radiolabeled pro-R
[4-3H]NADPH (20 µM) or pro-S
[4-3H]NADPH (18 µM) was tested with RDH11
using various retinals (1-3). The partition assay for retinal
reduction was used to measure the activity, as described under
"Materials and Methods." E, stereospecifically labeled
pro-R [15-3H]retinols (1',
all-trans-retinol; 2', 9-cis-retinol;
3', 11-cis-retinol, 40-60 µM) or
pro-S [15-3H]retinols (40-60
µM) were examined with RDH12 in the presence of NADP (700 µM) at pH 8.0. The partition assay for retinol oxidation
was used to measure the activity as described under "Materials and
Methods."
|
|
RDH11, RDH12, and RDH14 demonstrate a clear specificity for the
pro-S hydrogen on C4 of NADPH (shown only for one enzyme, Fig. 6D) and the pro-R hydrogen on
C15 of all highly active retinols (Fig. 6E).
These properties resemble those of the photoreceptor dehydrogenase,
prRDH (24, 31), and not those of the RPE enzyme RDH5 (16, 24), which is
active toward the pro-S position of both substrates. The
results also suggest that these enzymes catalyze the reaction in both
directions, NADPH/retinals
NADP/retinols. RDH11, RDH12, and RDH14
show equal utilization of 11-cis-retinal and
all-trans-retinal when these substrates are present at equal concentrations in the same mixture (data not shown), a property that
suggests similar efficiency toward both substrates. No steroid dehydrogenase activity was detected for RDH11, RDH12, and RDH14. The
activity of the RDH11-14, photoreceptor prRDH, and RDH5 was potently
inhibited by retinoic acids (for example, 9-cis-retinoic acid, KI ~1 µM for RDH11),
recombinant CRBP1 (Supplemental Table 1, prRDH), and CRALBP
(Supplemental Table 2, RDH5).
Co-purification of RDH5 and RDH11 and Expression of RDHs in
Immortal ARPE19 Cells--
When RDH5 was purified from RPE membranes
using anti-RDH5 monoclonal antibody affinity chromatography,
NAD(H)-dependent (RDH5) and NADP(H)-dependent
(RDH11) enzymes were also isolated based on immunoblotting and retinol
activity profiles (Fig. 7A).
The activity was suppressed by diluting [4-3H]NADH with
NADH and NADPH. Because the anti-RDH5 antibody did not cross-react with
RDH11 (Fig. 2A), these results suggest that both enzymes may
form a larger oligomeric structure and/or interact with each other.
However, when RDH5 was expressed and purified from insect cells using
anti-RDH5 monoclonal antibody affinity chromatography, only NADH- and
cis-retinoid preferable properties were observed (Fig.
7B). Qualitatively, the stereospecificity of the mixture of
RDHs isolated from RPE membranes (Fig. 7A) matched the sum
of stereo-preferences toward retinals of RDH5 (Fig. 7B) and
RDH11 (Figs. 5 and 6) or the sum of stereo-preferences of RDH5 (Fig.
7B) and the remaining activity in RPE membranes derived from
rdh5
/
mice (Fig. 7C). This suggests
that the enzyme responsible for oxidation of 11-cis-retinol
in these membranes is RDH11.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Enzymatic activities and RDH11
immunoreactivity of affinity column-purified of RDH5.
A, RDH5 from bovine RPE microsomes was purified as
described under "Materials and Methods." The assay with
pro-S [4-3H]NAD(P)H and geometric isomers of
retinals in the presence or absence of NAD(P)H was carried out for 50 min at 37 °C using the phase partition assay as described under
"Materials and Methods," and the amount of
[15-3H]retinol isomer was quantified. B,
RDH5-His6 from transfected Sf9 cells was purified as
described under "Materials and Methods." The assay was carried out
for 50 min at 37 °C using phase partition assay as described under
"Materials and Methods." Indicated is the amount of the
corresponding [15-3H]retinol isomer formed in pmol/min.
Inset, immunoblot of the purified fraction on anti-RDH5
antibody column probed with specific anti-RDH5 (lane 1) and
RDH11 antibodies (lane 3). Lane 2 is a 33-kDa
molecular marker. C, stereospecificity toward retinal in RPE
membranes derived from rdh5 / mice (16).
|
|
As with many enzymes involved in retinoid metabolism, the
expression of RDH11 and RDH5 are lost in ARPE19, an immortalized RPE
cell line (Supplemental Fig. 2A), although other functions of retinal epithelium are preserved. These cells also lack RDH activity
toward retinals (Supplemental Fig. 2B). These findings are
not due to a secondary effect caused by a lack of other
retinoid-processing enzymes because transfecting these cells with the
RDH11 or 12 cDNAs restores RDH activity. This observation supports
the hypothesis that RDH11 is involved in 11-cis-retinol
oxidation in the RPE (Supplemental Fig. 2C).
 |
DISCUSSION |
Dual-substrate Specificity, Dual Responsibility;
Mechanistic Considerations and Physiological Implications--
Studies
of stereochemical transformations catalyzed by RDH enzymes in native
tissues and in heterologous expression systems provide important
insights detailing physiological substrates, cofactors, and potential
complementary enzyme activities. Here, we demonstrated that RDH11-14
catalyze hydrogen transfer from the pro-S C4
position of NADPH but not of NADH. This specificity is also observed in
the eye, one of the most active tissues in retinoid metabolism (2, 24).
For all convergently evolved RDH enzymes from the SDR superfamily, only
one conformational orientation of dinucleotides within the binding site
has been observed. This is consistent with the structural conservation and rigidity of the Rossman fold (33-37). However, the binding of
hydrophobic substrates occurs in less conserved loop regions and can
take place by projecting the aldehyde group in re- or si-face orientation toward the nucleotide (24). It is
possible that RDH11-14 will have a mixed stereospecificity for
different geometric analogs. For RDH11-14, the binding of dramatically
different geometric isomers, such as all-trans-,
9-cis-, and 11-cis-retinoids and poor utilization
of 13-cis-retinol/al suggest that the enzymes specially
recognize the conformation along the C12-C15
carbon chain. The observed pro-R specificity of RDH12 is
identical to the specificity of prRDH, a photoreceptor RDH, and allows
its discrimination from other pro-S SDRs, including RDH5
(24). However, RDH11-14 differ even from prRDH and other RDHs, which
are sensitive for the location of the C15 atom and,
therefore, recognize cis or trans isomers. This
property also differs from that of two highly homologous tropinone
reductases that are members of the SDR superfamily and bind the same
substrate differently to produce two different conformations of the
product (36). The stereospecific enzymatic properties of RDH11 uniquely
match the RDH activity present in RPE membranes of rdh5
/
mice (16) and, together with high expression in RPE cells and formation
of a complex with RDH5, support the idea that RDH11 is the missing
enzyme of the visual cycle responsible for production of
11-cis- and all-trans-retinal. These studies also
provide a novel approach for the analysis of complex and redundant
enzymatic pathways and for the in-depth use of stereochemistry in
studies of metabolic transformations.
Retinoid Flow in the Eye--
RDH11 localizes in RPE, where it
likely plays a key role in producing the aldehyde forms of
all-trans and 11-cis isomers (Fig. 8). All-trans-retinal is
utilized by retinal G-protein-coupled receptor, a hypothetical
photoisomerase that is essential for replenishing
11-cis-retinals at high illumination levels (38). It has
been proposed that RDH5 forms a complex with this retinal G-protein-coupled receptor (39). Here, we showed that RDH11 may
interact with RDH5 (Fig. 7A), forming possible homo- and
heterodimeric or oligomeric complexes (7).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Isomeric specificity of the retinoid cycle
reactions in the vertebrate retina. Light causes the isomerization
of rhodopsin chromophore, 11-cis-retinal, to
all-trans-retinal, which is next reduced in the reaction
catalyzed by all-trans-retinal-specific RDH(s). This
dehydrogenase activity utilizes pro-S [4-Ha]
of NADPH and does not bind NADH to generate pro-R
[15-Ha]all-trans-retinol. Next,
pro-R [15-Ha]all-trans-retinol or
its derivative is isomerized with the inversion of the C15
prochiral methylene hydroxyl group configuration, specifically
generating pro-S
[15-Ha]11-cis-retinol isomer. Pro-S
[15-Ha]11-cis-retinol isomer is then oxidized
by RDH5 activity (resulting in the loss of pro-S
[15-Ha]) or by RDH11 (resulting in the loss of
pro-R [15-Hb]) to 11-cis-retinal
with concomitant generation of pro-S
[4-Ha]NADH or pro-S [4-Hb]NADPH
to complete the cycle (modified version from
(24)).
|
|
Another function of RDH11, along with RDH5, might be to produce
11-cis-retinal from 11-cis-retinol. RDH5 is
responsible for the majority of RDH activity in RPE membranes. In
humans, mutations in this gene are associated with fundus
albipunctatus, a disease expressed by delayed dark adaptation of both
cones and rods. Detailed analyses of rdh5
/
mice have
identified only a minor phenotype manifested by the accumulation of
13-cis-retinoids. These studies indicate that another enzyme
is responsible for the production of 11-cis-retinal under
bleaching conditions (16). The RDH(s) responsible for the production of
11-cis-retinal in RPE membrane from rdh5
/
mice display pro-S hydrogen specificity for NADPH and
utilize 9-cis- and 11-cis-retinal but not
13-cis-retinal (16). Furthermore, pro-R
stereospecificity toward 11-cis-retinol with NADP was
observed in bovine RPE (24). The pro-R stereospecificity toward the retinols is a rare property among SDRs. These results are in
perfect agreement with the properties of RDH11 determined in the
experiments reported here (Figs. 5-7). Therefore, it is highly probable that RDH11 is the missing enzyme of the RPE in vertebrates as
no other known RDH exhibits similar properties (Supplemental Table 3).
RDH12 is expressed in photoreceptor cells, although RDH14 appears to be
a minor enzymatic component of ocular retinoid metabolism based upon
its level of expression. The substrate specificity of RDH12 indicates
that it functions in a fashion complementary to previously identified
RDHs (31, 32) involved in the production of
all-trans-retinol from all-trans-retinal. We
hypothesize that RDH12 might be the key enzyme in the
formation of 11-cis-retinal from 11-cis-retinol
during regeneration of the cone visual pigments (for review, see Ref.
2).
Bliss reports that the equilibrium constant for reduction of
all-trans-retinal is 10
2 to 10 between pH 6.6 to 9.4, respectively (40). Depending on the layer of the retina, the
ratio of NADP to NADPH is between 4 to 1 and 1.5 to 1, whereas the
ratio of NAD to NADH could be as high as 300 to 1 (41). Therefore,
NAD-dependent enzymes will be mostly oxidizing RDHs,
whereas NADP-dependent enzymes will have the ability to
catalyze reactions in both directions depending on the retinol/retinal ratio.
Involvement of RDH11-14 in Retinoid Transformation and All-trans-
and 9-cis-Retinoic Acid Production--
The RDH5 gene
product has been implicated in the production of
9-cis-retinal before this aldehyde is further oxidized to
9-cis-retinoic acids (12, 14). However, disabling mutations
in men and mice produce no embryonic developmental abnormalities
(16-19). In this report, we provide unequivocal evidence that
RDH11-14 display high activity toward 9-cis- and
all-trans-retinol. The unique substrate utilization of
all-trans- and cis-retinoids combined with the
specific expression of these enzymes identifies a novel pathway
involving the cooperative production of both retinoic acids by the same
enzyme that may activate combinations of the retinoic acid receptor and
retinoid X receptor nuclear receptors (4). In addition, RDH11-14 may
participate in the reduction of all-trans-retinal and
9-cis-retinal because they are formed in reactions catalyzed
by dioxygenases from dietary 9-cis-
-carotene (42). These
retinols are stored in the form of retinyl esters before use. Because
9-cis-retinal is more stable than 9-cis-retinol, an alternative pathway in the production of 9-cis-isomers is
the isomerization of all-trans-retinol to
9-cis-retinol (43). Although the equilibrium is shifted
toward the all-trans-isomers (5), small amounts of
9-cis-retinal would be trapped as it is formed and further
oxidized by aldehyde dehydrogenases (44). These RDH properties do not
eliminate the possibility that these dehydrogenases may also be
involved in redox reactions of other unidentified lipophilic
substrates, as has been documented for other SDRs that are fairly
unrestricted in substrate recognition (9). SDRs are a redundant group
of enzymes regulated by the availability of hydrophobic substrates and
the redox potential of the subcellular compartments. However, the
localization of the RDH11-14 to cellular and subcellular ocular
compartments, where the traffic of retinoids is high, supports the idea
that these enzymes are involved in critical retinoid transformations
that mediate vision. Targeted genetic lesions that abolish individual
or combinations of dual-specificity SDR activities may serve to
further determine their specific roles in ocular and developmental processes.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Bryan S. Sires for assistance
with preparing human eye tissue from a donor. Legal requirements for
use of human donor retinas and primate retinas were met (University of
Washington Human Subjects, approval on file).
 |
FOOTNOTES |
*
This research was supported by National Institutes of Health
Grants EY08061, CA75173, and DK59125, a grant from Research to Prevent
Blindness, Inc. (to the Department of Ophthalmology, University of
Washington), and by the E. K. Bishop Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains Supplemental
Figs. 1 and 2 and Tables 1-3.
§
These authors contributed equally to this work.
§§
Recipient of a Research to Prevent Blindness Senior Investigator
Award. To whom correspondence should be addressed: Dept. of
Ophthalmology, University of Washington, Seattle, WA 98195. Tel.:
206-543-9074; Fax: 206-221-6784; E-mail:
palczews@u.washington.edu.
Published, JBC Papers in Press, September 10, 2002, DOI 10.1074/jbc.M208882200
 |
ABBREVIATIONS |
The abbreviations used are:
RPE, retinal pigment
epithelial (cells);
SDR, short chain alcohol dehydrogenase/reductase;
RDH, retinol dehydrogenase;
prRDH, photoreceptor RDH;
HPLC, high
performance liquid chromatography;
DTT, dithiothreitol;
MES, 4-morpholineethanesulfonic acid;
EST, expressed sequence tag;
kb, kilobases;
ROS, rod outer segments;
BTP, 1,3-bis[tris(hydroxymethyl)methylamino] propane.
 |
REFERENCES |
| 1.
|
Polans, A.,
Baehr, W.,
and Palczewski, K.
(1996)
Trends Neurosci.
19,
547-554[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
McBee, J. K.,
Palczewski, K.,
Baehr, W.,
and Pepperberg, D. R.
(2001)
Prog. Retin. Eye Res.
20,
469-529[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Leid, M.,
Kastner, P.,
and Chambon, P.
(1992)
Trends Biochem. Sci
17,
427-433[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Mangelsdorf, D. J.,
Thummel, C.,
Beato, M.,
Herrlich, P.,
Schutz, G.,
Umesono, K.,
Blumberg, B.,
Kastner, P.,
Mark, M.,
and Chambon, P.
(1995)
Cell
83,
835-839[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
McBee, J. K.,
Van Hooser, J. P.,
Jang, G. F.,
and Palczewski, K.
(2001)
J. Biol. Chem.
276,
48483-48493[Abstract/Free Full Text]
|
| 6.
|
Napoli, J. L.
(1999)
Biochim. Biophys. Acta
1440,
139-162[Medline]
[Order article via Infotrieve]
|
| 7.
|
Jornvall, H.,
Persson, B.,
Krook, M.,
Atrian, S.,
Gonzalez-Duarte, R.,
Jeffery, J.,
and Ghosh, D.
(1995)
Biochemistry
34,
6003-6013[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Chou, C. F.,
Lai, C. L.,
Chang, Y. C.,
Duester, G.,
and Yin, S. J.
(2002)
J. Biol. Chem.
277,
25209-25216[Abstract/Free Full Text]
|
| 9.
|
Biswas, M. G.,
and Russell, D. W.
(1997)
J. Biol. Chem.
272,
15959-15966[Abstract/Free Full Text]
|
| 10.
|
Driessen, C. A.,
Janssen, B. P.,
Winkens, H. J.,
van Vugt, A. H.,
de Leeuw, T. L.,
and Janssen, J. J.
(1995)
Investig. Ophthalmol. Vis. Sci.
36,
1988-1996[Abstract/Free Full Text]
|
| 11.
|
Simon, A.,
Hellman, U.,
Wernstedt, C.,
and Eriksson, U.
(1995)
J. Biol. Chem.
270,
1107-1112[Abstract/Free Full Text]
|
| 12.
|
Paik, J.,
Vogel, S.,
Piantedosi, R.,
Sykes, A.,
Blaner, W. S.,
and Swisshelm, K.
(2000)
Biochemistry
39,
8073-8084[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Mertz, J. R.,
Shang, E.,
Piantedosi, R.,
Wei, S.,
Wolgemuth, D. J.,
and Blaner, W. S.
(1997)
J. Biol. Chem.
272,
11744-11749[Abstract/Free Full Text]
|
| 14.
|
Romert, A.,
Tuvendal, P.,
Simon, A.,
Dencker, L.,
and Eriksson, U.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4404-4409[Abstract/Free Full Text]
|
| 15.
|
Driessen, C. A.,
Winkens, H. J.,
Kuhlmann, E. D.,
Janssen, A. P.,
van Vugt, A. H.,
Deutman, A. F.,
and Janssen, J. J.
(1998)
FEBS Lett.
428,
135-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Jang, G. F.,
Van Hooser, J. P.,
Kuksa, V.,
McBee, J. K., He, Y. G.,
Janssen, J. J.,
Driessen, C. A.,
and Palczewski, K.
(2001)
J. Biol. Chem.
276,
32456-32465[Abstract/Free Full Text]
|
| 17.
|
Driessen, C. A.,
Winkens, H. J.,
Hoffmann, K.,
Kuhlmann, L. D.,
Janssen, B. P.,
Van Vugt, A. H.,
Van Hooser, J. P.,
Wieringa, B. E.,
Deutman, A. F.,
Palczewski, K.,
Ruether, K.,
and Janssen, J. J.
(2000)
Mol. Cell. Biol.
20,
4275-4287[Abstract/Free Full Text]
|
| 18.
|
Yamamoto, H.,
Simon, A.,
Eriksson, U.,
Harris, E.,
Berson, E. L.,
and Dryja, T. P.
(1999)
Nat. Genet.
22,
188-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Cideciyan, A. V.,
Haeseleer, F.,
Fariss, R. N.,
Aleman, T. S.,
Jang, G. F.,
Verlinde, C. L.,
Marmor, M. F.,
Jacobson, S. G.,
and Palczewski, K.
(2000)
Visual Neurosci.
17,
667-678[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Lin, B.,
White, J. T.,
Ferguson, C.,
Wang, S.,
Vessella, R.,
Bumgarner, R.,
True, L. D.,
Hood, L.,
and Nelson, P. S.
(2001)
Cancer Res.
61,
1611-1618[Abstract/Free Full Text]
|
| 21.
|
Kedishvili, N. Y.,
Chumakova, O. V.,
Chetyrkin, S. V.,
Belyaeva, O. V.,
Lapshina, E. A.,
Lin, D. W.,
Matsumura, M.,
and Nelson, P. S.
(2002)
J. Biol. Chem.
277,
28909-28915[Abstract/Free Full Text]
|
| 22.
|
Haeseleer, F.,
Imanishi, Y.,
Saperstein, D. A.,
and Palczewski, K.
(2001)
Investig. Ophthalmol. Vis. Sci.
42,
3294-3300[Abstract/Free Full Text]
|
| 23.
|
Imanishi, Y., Li, N.,
Sokal, I.,
Sowa, M. E.,
Lichtarge, O.,
Wensel, T. G.,
Saperstein, D. A.,
Baehr, W.,
and Palczewski, K.
(2002)
Eur. J. Neurosci.
15,
63-78[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Jang, G. F.,
McBee, J. K.,
Alekseev, A. M.,
Haeseleer, F.,
and Palczewski, K.
(2000)
J. Biol. Chem.
275,
28128-28138[Abstract/Free Full Text]
|
| 25.
|
Papermaster, D. S.
(1982)
Methods Enzymol.
81,
48-52[Medline]
[Order article via Infotrieve]
|
| 26.
|
Stecher, H.,
Gelb, M. H.,
Saari, J. C.,
and Palczewski, K.
(1999)
J. Biol. Chem.
274,
8577-8585[Abstract/Free Full Text]
|
| 27.
|
Mercer, E. I.,
and Scott, T. A.
(1997)
Concise Encyclopedia of Biochemistry and Molecular Biology
, Walter de Gruyter & Co., Berlin
|
| 28.
|
Palczewski, K.,
Jager, S.,
Buczylko, J.,
Crouch, R. K.,
Bredberg, D. L.,
Hofmann, K. P.,
Asson-Batres, M. A.,
and Saari, J. C.
(1994)
Biochemistry
33,
13741-13750[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Saari, J. C.,
Garwin, G. G.,
Haeseleer, F.,
Jang, G. F.,
and Palczewski, K.
(2000)
Methods Enzymol.
316,
359-371[Medline]
[Order article via Infotrieve]
|
| 30.
|
Romert, A.,
Tuvendal, P.,
Tryggvason, K.,
Dencker, L.,
and Eriksson, U.
(2000)
Exp. Cell Res.
256,
338-345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Rattner, A.,
Smallwood, P. M.,
and Nathans, J.
(2000)
J. Biol. Chem.
275,
11034-11043[Abstract/Free Full Text]
|
| 32.
|
Haeseleer, F.,
and Palczewski, K.
(2000)
Methods Enzymol.
316,
372-383[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Ghosh, D.,
Wawrzak, Z.,
Weeks, C. M.,
Duax, W. L.,
and Erman, M.
(1994)
Structure (Lond.)
2,
629-640[Medline]
[Order article via Infotrieve]
|
| 34.
|
Bennett, M. J.,
Schlegel, B. P.,
Jez, J. M.,
Penning, T. M.,
and Lewis, M.
(1996)
Biochemistry
35,
10702-10711[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Tanaka, N.,
Nonaka, T.,
Tanabe, T.,
Yoshimoto, T.,
Tsuru, D.,
and Mitsui, Y.
(1996)
Biochemistry
35,
7715-7730[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Nakajima, K.,
Yamashita, A.,
Akama, H.,
Nakatsu, T.,
Kato, H.,
Hashimoto, T.,
Oda, J.,
and Yamada, Y.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4876-4881[Abstract/Free Full Text]
|
| 37.
|
Grimm, C.,
Maser, E.,
Mobus, E.,
Klebe, G.,
Reuter, K.,
and Ficner, R.
(2000)
J. Biol. Chem.
275,
41333-41339[Abstract/Free Full Text]
|
| 38.
|
Chen, P.,
Hao, W.,
Rife, L.,
Wang, X. P.,
Shen, D.,
Chen, J.,
Ogden, T.,
Van Boemel, G. B., Wu, L.,
Yang, M.,
and Fong, H. K.
(2001)
Nat. Genet.
28,
256-260[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Chen, P.,
Lee, T. D.,
and Fong, H. K.
(2001)
J. Biol. Chem.
276,
21098-21104[Abstract/Free Full Text]
|
| 40.
|
Bliss, A. F.
(1951)
Arch. Biochem. Biophys.
31,
197-204[CrossRef]
|
| 41.
|
Matschinsky, F. M.
(1968)
J. Neurochem.
15,
643-657[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Nagao, A.,
and Olson, J. A.
(1994)
FASEB J.
8,
968-973[Abstract]
|
| 43.
|
Van Hooser, J. P.,
Aleman, T. S., He, Y. G.,
Cideciyan, A. V.,
Kuksa, V.,
Pittler, S. J.,
Stone, E. M.,
Jacobson, S. G.,
and Palczewski, K.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8623-8628[Abstract/Free Full Text]
|
| 44.
|
Napoli, J. L.
(1996)
FASEB J.
10,
993-1001[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit